Loading…
ACADIA Pharmaceuticals Inc. is projected to rise to $36.97 by 2027, a +41% move from its current price of $26.22. ACAD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $25.77 | $26.22 | $26.67 | 0.00% |
| Jul 13 | $25.59 | $26.22 | $26.86 | -0.01% |
| Jul 14 | $25.45 | $26.22 | $27.01 | -0.01% |
| Jul 15 | $25.33 | $26.22 | $27.13 | -0.02% |
| Jul 16 | $25.22 | $26.21 | $27.24 | -0.02% |
| Jul 17 | $25.13 | $26.21 | $27.34 | -0.03% |
| Jul 18 | $25.04 | $26.21 | $27.43 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $25.04 | $26.21 | $27.43 | -0.03% |
| Week 2 | $24.57 | $26.20 | $27.95 | -0.06% |
| Week 3 | $24.21 | $26.20 | $28.35 | -0.09% |
| Week 4 | $23.91 | $26.19 | $28.69 | -0.12% |
| Week 5 | $23.64 | $26.18 | $28.99 | -0.15% |
| Week 6 | $23.41 | $26.17 | $29.26 | -0.18% |
| Week 7 | $23.19 | $26.16 | $29.52 | -0.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development and commercialization of medicines for neurological and rare diseases in North America.
Its pipeline includes NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. The company also develops other programs in various phases of clinical trials and has licensing agreements with Neuren Pharmaceuticals Limited for trofinetide and with Stoke Therapeutics, Inc. ACADIA was incorporated in 1993, is headquartered in San Diego, California, and was formerly known as Receptor Technologies, Inc.
ACADIA operates in the healthcare sector, with a focus on neuroscience and rare diseases, and maintains a portfolio that spans late-stage programs and early-stage discoveries aimed at expanding treatment options for complex disorders in North America.
ACADIA Pharmaceuticals Inc. currently trades at $25.32 per share and has a market capitalization of $4.34B. It is ranked 1484 in market size.
The current price is complemented by a year-by-year forecast that projects a bullish longer-term trajectory, beginning with 2026 and extending to 2050. The forecast provides annual average prices and ROI figures, illustrating potential upside over time.
A major floor 27.6% below — a decisive break under it would weaken the trend.
The nearest floor, 20.3% below — buyers have tended to step in here.
Price is pressing into resistance (0.7% away) — a breakout level to watch.
A major ceiling 14.5% above — clearing it would confirm fresh momentum.
Key ACAD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACAD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $26.12 | Buy | $26.06 | Buy |
| MA 10 | $25.76 | Buy | $25.48 | Buy |
| MA 20 | $23.86 | Buy | $24.43 | Buy |
| MA 50 | $22.52 | Buy | $23.19 | Buy |
| MA 100 | $22.40 | Buy | $22.95 | Buy |
| MA 200 | $23.31 | Buy | $22.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 73.31 | Sell |
| Stoch RSI (14) | 78.70 | Neutral |
| CCI (20) | 82.88 | Neutral |
| Williams %R (14) | -4.40 | Info |
| MACD (12,26,9) | 0.23 | Buy |
| ROC (12) | 16.02 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 95.60 | Sell |
| TRIX (15) | 0.64 | Buy |
| Awesome (5,34) | 3.26 | Buy |
| Ultimate (7,14,28) | 75.10 | Sell |
| Momentum (10) | 2.50 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 26.43 | Sell |
| ADX (14) | 32.39 | Buy |
| ATR (14) | 0.37 | Info |
The 30-day technical picture signals bullish momentum with RSI14 at 70, indicating strong near-term upside pressure.
The stock’s short-term moving averages show SMA50 at $21.78 and SMA200 at $23.24, suggesting a near-term trend above key moving averages. Support is identified at $20.48 and resistance at $23.72, with a 30-day price range between $22.72 and $28.22.
The annualized volatility is 30, reflecting notable near-term variability in the price path.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $20.32 | $26.22 | $32.86 | 0% | Neutral | |
| $30.27 | $36.97 | $47.19 | +41% | Bullish | |
| $33.94 | $42.22 | $55.36 | +61% | Bullish | |
| $36.81 | $46.50 | $62.27 | +77% | Bullish | |
| $41.78 | $53.48 | $72.91 | +104% | Bullish | |
| $43.49 | $56.36 | $78.04 | +115% | Bullish | |
| $49.18 | $64.45 | $90.52 | +146% | Bullish | |
| $58.81 | $77.88 | $110.79 | +197% | Bullish | |
| $65.77 | $87.96 | $126.63 | +235% | Bullish | |
| $73.75 | $99.57 | $144.93 | +280% | Bullish | |
| $112.72 | $158.73 | $242.12 | +505% | Bullish | |
| $185.25 | $279.78 | $457.47 | +967% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $20.32 | $26.22 | $30.80 | +0.00% |
| August 2026 | $21.89 | $25.63 | $30.66 | -2.24% |
| September 2026 | $22.20 | $26.12 | $31.48 | +1.89% |
| October 2026 | $22.52 | $26.60 | $32.27 | +1.84% |
| November 2026 | $22.25 | $26.37 | $32.18 | -0.85% |
| December 2026 | $22.53 | $26.79 | $32.86 | +1.60% |
Click any year to see its month-by-month ACAD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ACAD price prediction for 2026 points to an average of $26.22 (low $20.32, high $32.86) — a potential gain of 0% on today's $26.22. Price action looks broadly range-bound.
In 2027, ACAD is projected to trade between $30.27 and $47.19, averaging $36.97 — a potential gain of +41% from today's $26.22. That is up +41% on the projected 2026 average. Buyers look set to stay in control over this stretch.
ACADIA Pharmaceuticals Inc.'s 2028 outlook centres on $42.22, within a $33.94 to $55.36 range. That is up +14% on the projected 2027 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2029, ACAD could reach as high as $62.27, with a base case around $46.50 and support toward $36.81 — roughly +77% from $26.22. Buyers look set to stay in control over this stretch.
Expect ACAD to range from $41.78 to $72.91 through 2030. The $53.48 average target implies a +104% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The ACAD price prediction for 2031 points to an average of $56.36 (low $43.49, high $78.04) — a potential gain of +115% on today's $26.22. Buyers look set to stay in control over this stretch.
In 2032, ACAD is projected to trade between $49.18 and $90.52, averaging $64.45 — a potential gain of +146% from today's $26.22. That is up +14% on the projected 2031 average. Momentum favours further upside here.
ACADIA Pharmaceuticals Inc.'s 2033 outlook centres on $77.88, within a $58.81 to $110.79 range. That is up +21% on the projected 2032 average. That marks a +197% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ACAD could reach as high as $126.63, with a base case around $87.96 and support toward $65.77 — roughly +235% from $26.22. Momentum favours further upside here.
Expect ACAD to range from $73.75 to $144.93 through 2035. The $99.57 average target implies a +280% move from current prices. That is up +13% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ACAD price prediction for 2040 points to an average of $158.73 (low $112.72, high $242.12) — a potential gain of +505% on today's $26.22. Momentum favours further upside here.
In 2050, ACAD is projected to trade between $185.25 and $457.47, averaging $279.78 — a potential gain of +967% from today's $26.22. That is up +76% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACAD today (≈ 38.138825 ACAD) could be worth
$10,670.52
+$9,670.52 (+967%) by 2050 · US Dollar
Based on the average projected ACAD price of $279.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACADwould be worth at today's price.
$1,000 invested in ACAD on Jul 10, 2025 (≈ 45.330917 ACAD) would be worth
$1,188.58
+$188.58 (+18.9%) today · 1.19× · US Dollar
Based on a ACAD entry price of $22.06 vs. today's $26.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $25.97 | $1,009.63 | +1.0% |
| 1 month ago | $21.25 | $1,233.88 | +23.4% |
| 3 months ago | $21.74 | $1,206.07 | +20.6% |
| 6 months ago | $26.59 | $986.08 | -1.4% |
| 1 year ago | $22.06 | $1,188.58 | +18.9% |
| All time (5.0y) ago | $23.74 | $1,104.47 | +10.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACAD forecast.
Our base-case forecast reaches $52.00 around 2030.
Implied market cap at $52.00: $8.9B
The multi-year forecast presents a rising trajectory in average prices and robust upside potential. In 2026, the min is $20.32, the avg is $25.32, and the max is $32.16, with a ROI of 0 and a neutral sentiment. By 2027, the avg increases to $35.16 and the min/max move to $28.77/$44.94, with a ROI of 38.9 and a bullish sentiment; by 2028, the avg is $39.32 and the min/max are $31.59/$51.60, ROI 55.3, bullish.
Through 2030 the avg price rises to $49.40 (min $38.57, max $67.39) with ROI 95.1 and bullish sentiment, and by 2031 the avg is $51.01 (min $39.34, max $70.67) with ROI 101.5. The forecast continues higher, with 2032 avg $58.47 (min $44.60, max $82.16), ROI 130.9, 2033 avg $69.76 (min $52.66, max $99.29), ROI 175.5, and 2034 avg $77.90 (min $58.22, max $112.19), ROI 207.7, all with bullish sentiment. By 2035 the avg is $89.08 (min $65.96, max $129.72) ROI 251.8 and bullish.
The path extends to 2040 with avg $135.64 (min $96.30, max $206.98), ROI 435.7, bullish; and to 2050 with avg $240.78 (min $159.39, max $393.78), ROI 850.9, bullish. These figures imply sustained upside across the horizon, though they are estimates and carry inherent uncertainty and risk.
Tap a question to reveal the answer.
The forecast shows 2030 with min $38.57, avg $49.40, max $67.39; ROI 95.1; sentiment bullish.
The forecast indicates bullish potential over the long term, with 2030–2050 average prices rising to $49.40, $135.64 by 2040, and $240.78 by 2050, and ROI reaching 95.1% in 2030 and 850.9% in 2050. These are estimates, not guarantees, and actual results may vary.
Yes, the forecast shows the average price surpassing $100 by 2040 (avg $135.64). Earlier years show lower averages, but the long-run path indicates potential above $100 this decade and beyond.
Current price is $25.32 and market capitalization is $4.34B.
RSI14 is 70, indicating bullish momentum. The 30-day range is $22.72 to $28.22, with SMA50 at $21.78 and SMA200 at $23.24 and support at $20.48 and resistance at $23.72.
ACADIA Pharmaceuticals Inc. Community Discussion
0Share your ACADIA Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.